Sign in
Taking peopleNo phase

Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock

Key facts

Who runs it
University Hospital, Clermont-Ferrand
Where
France29 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
750 people, planned
Started
29 Mar 2026
Expected to end
31 Dec 2027
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • CO2gap-guided resuscitation strategy
Record updated
28 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Patients aged 18 years or older AND
  • Acutely admitted to a study ICU AND
  • Primary diagnosis of septic shock according to the Sepsis-3 criteria and defined as:; A suspected or documented site of infection or positive blood culture AND; Acute increase of at least 2 points in the Sequential Organ Failure Assessment (SOFA) score consequent to the infection AND; Having a serum lactate level >2 mmol/l AND; Requirement of vasopressors (any dose of norepinephrine) to maintain mean arterial pressure (MAP) ≥65 mmHg despite adequate fluid resuscitation (at least 1L of IV fluid in the last 24 hours prior to screening)

Who cannot take part

  • Anticipated surgery during the first 24 hours after randomization
  • Prior enrollment in the CARBON trial
  • Primary cause of hypotension not due to sepsis (e.g., acute bleeding)
  • Death is deemed to be imminent or inevitable or patients with an underlying disease process with a life expectancy of less than 3 months
  • Septic shock for more than 12 hours at the time of screening
  • Decision not to resuscitate (or to limit full care) or not to intubate taken before obtaining consent
  • Patient or their relatives' refusal to participate
  • Patients participating in another RCT with interventions possibly compromising the primary outcome
  • Known to be pregnant
  • Legal protection (i.e., incompetence to provide consent and no guardian or incarceration)
  • No affiliation with the French health care system

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Sepsis is a dysregulated host response to infection that leads to life-threatening organ dysfunction and represents a major healthcare problem. Septic shock is the most severe form, characterized by increased capillary permeability and vasodilation, resulting in hypotension and tissue hypoxia. Early identification and treatment of tissue hypoperfusion are pivotal components of initial resuscitation to limit progression to multiple organ dysfunction and death. The 2021 Surviving Sepsis Guidelines recommend guiding initial resuscitation by targeting decreases in serum lactate levels in patients with elevated lactate. However, although elevated lactate levels may reflect tissue hypoxia, serum lactate is not a direct marker of tissue perfusion. Hyperlactatemia may be attributable to mechanisms other than tissue hypoperfusion, such as accelerated aerobic glycolysis driven by excessive β-adrenergic stimulation or impaired clearance (e.g., in liver failure).

Read full original descriptionShow less

The venous-to-arterial carbon dioxide partial pressure difference (CO₂ gap), which is inversely related to cardiac output, has been shown to reflect the adequacy of venous blood flow to remove CO₂ from tissues. The CO₂ gap is closely linked to microcirculatory blood flow during the early resuscitation phase of septic shock and may effectively identify persistent tissue hypoperfusion in shock states. A persistently high CO₂ gap during early resuscitation has been associated with significantly higher 28-day mortality and increased Sequential Organ Failure Assessment (SOFA) scores. Moreover, the CO₂ gap has been shown to respond to changes in cardiac output during inotrope infusion in patients with low blood flow, suggesting that its assessment could be useful for therapeutic adjustments. Therefore, there are compelling arguments to evaluate the usefulness of the CO₂ gap in guiding early resuscitation in patients with septic shock.

The investigators postulated that CO₂ gap-guided early resuscitation may be more effective in improving outcomes than lactate-guided resuscitation.

The 2 groups in the trial

  • CO2gap-guided resuscitation strategyTreatment being tested

    CO2gap-guided resuscitation strategy aimed at maintaining central venous-to-arterial CO2 partial pressure difference (CO2gap) lower than 6 mmHg, using a sequential approach through a dedicated hemodynamic algorithm. Arterial and central venous blood samples will be drawn simultaneously and reassessed at 2 to 4-hour intervals

  • Lactate level-guided resuscitation strategyNo study treatment, for comparison

    Lactate level-guided resuscitation strategy aimed at normalizing or decreasing lactate levels by 20% at 2 to 4-hour intervals, as per the surviving sepsis campaign guidelines.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock: A Multicenter Prospective Randomized Trial (CARBON)
Record updated
28 October 2026